Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Common Equity (2016 - 2025)

Jaguar Health (JAGX) has disclosed Common Equity for 11 consecutive years, with $4.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 66.72% to $4.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.4 million, a 66.72% decrease, with the full-year FY2024 number at $6.5 million, up 32.61% from a year prior.
  • Common Equity was $4.4 million for Q3 2025 at Jaguar Health, down from $6.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $31.9 million in Q1 2021 to a low of -$1.4 million in Q4 2022.
  • A 5-year average of $10.0 million and a median of $6.9 million in 2025 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 1958.61% in 2021, then tumbled 111.47% in 2022.
  • Jaguar Health's Common Equity stood at $11.9 million in 2021, then crashed by 111.47% to -$1.4 million in 2022, then surged by 460.34% to $4.9 million in 2023, then skyrocketed by 32.61% to $6.5 million in 2024, then plummeted by 32.88% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Common Equity are $4.4 million (Q3 2025), $6.9 million (Q2 2025), and $830000.0 (Q1 2025).